Effect | None |
Trial Design | Double blind |
Trial Length | 2-4 Weeks |
Number of Subjects | 36 |
Sex | Both Genders |
Age Range | 30-44, 45-64 |
Supplementation of valerian valepotriates at 81.3mg daily for four weeks in persons with diagnosed generalized anxiety disorder (GAD) compared to both placebo and diazepam noted that the valepotriates were not significantly effective relative to placebo despite a positive trend.
There was no significant difference between valepotriates and diazepam either on HAM-A (a rating scale), although diazepam outperformed valepotriates on the STAI-Trait rating scale.